Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock

Neos Therapeutics (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced the pricing of an underwritten public offering of 17,391,304 shares of its common stock at a price to the public of $2.30 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos.

As quoted in the press release:

In addition, Neos has granted the underwriter a 30-day option to purchase up to an additional 2,608,695 shares of its common stock at the public offering price, less underwriting discounts and commissions. This offering is expected to close on November 8, 2018, subject to customary closing conditions.

Cantor Fitzgerald & Co is acting as sole bookrunner and JMP Securities LLC is acting as lead manager for the offering.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-212809), including a base prospectus, filed by Neos on August 1, 2016 and declared effective by the Securities and Exchange Commission, or the SEC, on August 12, 2016. The offering was made only by means of a prospectus.  A preliminary prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on November 5, 2018 and is available on the SEC’s website at www.sec.gov.

Click here to read the full press release.